Core Viewpoint - A-share companies are expected to report significant profit growth for 2025, with several companies projecting year-on-year increases exceeding 100% [1][2]. Group 1: Company Performance Forecasts - Baiwei Storage anticipates a net profit of 850 million to 1 billion yuan for 2025, representing a year-on-year growth of 427.19% to 520.22% [2][4]. - Chenguang Biological expects a net profit of 350 million to 405 million yuan for 2025, with a growth rate of 272.14% to 330.62% [2][9]. - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, indicating a growth of 169% to 191% [2][9]. - Dazhu CNC predicts a net profit of 785 million to 885 million yuan for 2025, with a growth of 160.64% to 193.84% [2][10]. - WoHua Pharmaceutical expects a net profit of 80 million to 115 million yuan for 2025, with a growth rate of 119.76% to 215.90% [2][11]. - Haopeng Technology anticipates a net profit of 195 million to 220 million yuan for 2025, with a growth of 113.69% to 141.09% [2][11]. - Changlan Technology forecasts a net profit of 130 million to 160 million yuan for 2025, with a growth of 74.07% to 114.24% [2][11]. Group 2: Factors Driving Growth - Baiwei Storage attributes its significant profit growth to a recovery in storage prices and the delivery of key projects, leading to improved sales revenue and gross margins [4][5]. - Chenguang Biological's growth is driven by increased revenue and gross profit from its plant extraction business, particularly in chili red and other products [9]. - TCL Technology's growth is supported by its focus on semiconductor displays, new energy photovoltaics, and semiconductor materials, achieving high-quality growth with substantial revenue and cash flow [9]. - Dazhu CNC's growth is fueled by rising demand for high-layer boards and PCB manufacturing driven by AI infrastructure investments [10]. Group 3: Market Trends and Investment Opportunities - The report from CICC highlights that the upcoming earnings disclosures may reveal sectors and companies with improved or exceeding expectations, which could attract investor attention [2]. - Key areas of focus include sectors benefiting from AI technology, such as TMT, innovative pharmaceuticals, energy storage, and solid-state batteries, which are entering a growth cycle [11][12]. - The report suggests that companies with overseas expansion strategies, particularly in home appliances, engineering machinery, and non-ferrous metals, may present reliable growth opportunities [11][12].

A股亮眼"成绩单"密集来袭！ 1月13日晚间，不少A股公司发布业绩预告。其中，多家公司的业绩大幅增长：佰维存储预计2025年净利同比增长427.19%—520.22%；晨光生物预计2025年净利同比增 长272.14%—330.62%；TCL科技2025年净利同比预增169%—191%；大族数控2025年净利同比预增160.64%—193.84%。此外，沃华医药、豪鹏科技的业绩增幅也在 100%以上。 | | 部分预告业绩翻倍的公司 | | | --- | --- | --- | | 公司名称 | 预计2025年归母净利润 | 同比增长幅度 | | 佰维存储 | 8.5亿元一 10亿元 | 427.19%- 520.22% | | 晨光生物 | 3.5亿元-4.05亿元 10 | 272.14%- 330.62% | | TCL科技 | 42.1亿元- 45.5亿元 | 169%- 191% | | 大族数控 | 7.85亿元- 8.85亿元 | 160.64%- 193.84% | | 沃华医药 | 0.8亿元- 1.15亿元 | 119.76%- 215.90% | | 豪鹏科技 | 1.95亿元一 2. ...

A股亮眼"成绩单"密集来袭！ 1月13日晚间，不少A股公司发布业绩预告。其中，多家公司的业绩大幅增长：佰维存储预计2025年净 利同比增长427.19%—520.22%；晨光生物预计2025年净利同比增长272.14%—330.62%；TCL科技2025 年净利同比预增169%—191%；大族数控2025年净利同比预增160.64%—193.84%。此外，沃华医药、豪 鹏科技的业绩增幅也在100%以上。 | | 部分预告业绩翻倍的公司 | | | --- | --- | --- | | 公司名称 | 预计2025年归母净利润 | 同比增长幅度 | | 佰维存储 | 8.5亿元一 10亿元 | 427.19%- 520.22% | | 晨光生物 | 3.5亿元-4.05亿元 12 | 272.14%- 330.62% | | TCL科技 | 42.1亿元- 45.5亿元 | 169%- 191% | | 大族数控 | 7.85亿元- 8.85亿元 | 160.64%- 193.84% | | 沃华医药 | 0.8亿元-1.15亿元 | 119.76%- 215.90% | | 豪鹏科技 | 1.95亿元-2.2 ...

谈及晨光生物的业绩爆发，添翼数字经济智库高级研究员吴婉莹对《证券日报》记者表示，晨光生物 2025年度业绩表现十分亮眼，其基石业务辣椒红销量稳居全球领先地位，辣椒精作为高附加值产品销量 激增，成为业绩增长的重要引擎；同时，通过主动优化棉籽类业务结构，聚焦加工并受益于行业回暖， 成功实现扭亏为盈，从拖累转为盈利贡献点。整体来看，公司通过核心产品放量、业务结构优化及行业 景气回升，实现了规模与盈利能力的同步大幅提升，展现出强劲的发展动能。 中国企业联合会特约研究员胡麒牧对记者进一步分析道："作为全球重要的植物提取物生产企业，晨光 生物在原料采购、生产工艺、成本控制等方面构建了深厚的竞争壁垒。辣椒红销量突破万吨、辣椒精增 速超60%，体现了公司核心产品的市场认可度和议价能力。而棉籽类业务扭亏为盈，反映出公司在业务 结构优化和行业周期把握上的成熟运营能力，通过收缩低毛利贸易业务，聚焦高附加值加工环节，成功 抓住了行业复苏的机遇。" 对于植提行业的未来发展，胡麒牧认为："随着消费者健康意识提升和食品工业的升级，天然植物提取 物作为安全、健康的添加剂，市场需求将持续扩大。晨光生物在叶黄素、辣椒提取物等细分领域的技术 优势 ...

2025年，植提类业务实现的收入和毛利额同比增长，是公司发展的基石，其中辣椒红实现销量1万吨以 上，同比增长约27%；辣椒精销量约2900吨，同比增长约65%；叶黄素销量约4.6亿克，同比略有下降。 棉籽类业务减少了贸易业务，实现收入约29亿元，同比有所下降，但随着行情回暖，产品利润率回升， 同比实现扭亏为盈。综上影响，公司整体业绩较上年同期上升。经初步测算，预计2025年实现营业收入 约66亿元，实现归属于上市公司股东的净利润为35,000万元—40,500万元，同比增长272.14%至 330.62%，其中非经常性损益影响金额约7,600万元。 格隆汇1月13日丨晨光生物(300138.SZ)公布，预计2025年归属于上市公司股东的净利润35,000万元— 40,500万元，比上年同期增长272.14%至330.62%，归属于上市公司股东扣除非经常性损益后的净利润 27,400万元—32,900万元，比上年同期增长519.13%至643.41%。 ...

每经AI快讯，1月13日，晨光生物(300138.SZ)公告称，预计2025年归属于上市公司股东的净利润为3.50 亿元—4.05亿元，比上年同期增长272.14%至330.62%。2025年，植提类业务实现的收入和毛利额同比增 长，是公司发展的基石，其中辣椒红实现销量1万吨以上，同比增长约27%；辣椒精销量约2900吨，同 比增长约65%；叶黄素销量约4.6亿克，同比略有下降。棉籽类业务减少了贸易业务，实现收入约29亿 元，同比有所下降，但随着行情回暖，产品利润率回升，同比实现扭亏为盈。综上影响，公司整体业绩 较上年同期上升。 ...

晨光生物公告，预计2025年度净利润为3.5亿元—4.05亿元，同比增长272.14%至330.62%。2025年，植 提类业务实现的收入和毛利额同比增长，是公司发展的基石，其中辣椒红实现销量1万吨以上，同比增 长约27%；辣椒精销量约2900吨，同比增长约65%；叶黄素销量约4.6亿克，同比略有下降。棉籽类业务 减少了贸易业务，实现收入约29亿元，同比有所下降，但随着行情回暖，产品利润率回升，同比实现扭 亏为盈。 ...

文 ｜ 海若镜 封面来源 ｜ 企业供图 36氪获悉，"微元合成"近日获近3亿元新一轮股权融资，投资方包括北京市新材料产业投资基金、北京市医药健康产业投资基 金、建信投资和中关村资本。 据了解，微元合成已完成多项人类营养、动物营养产品的研发和产业化，如阿洛酮糖、叶黄素、甘露醇等。本轮融资将重点用于 加快甲醇生物制造大宗生物基产品管线的研发与布局。 现阶段，以合成生物技术为基础的生物制造赛道，已从技术崇拜走向务实的产能及商业化落地。回顾过去几年间微元合成的选品 及开发路径，可见其发展逻辑：首先，敬畏市场，找到真实的市场需求；通过合成生物技术降本增效、建立壁垒；为管线产业化 调动多方的资源投入。 在人类营养领域，微元合成已在阿洛酮糖等核心单品开发上取得实质性商业进展。2025年7月，微元合成正式获得国家卫生健康 委员会新食品原料公告行政许可，成为全国首家通过生物发酵工艺获批阿洛酮糖生产的企业。 微元合成利用甲醇作为底盘原料，不仅能通过技术路径创新，生产大宗氨基酸以缓解中国对进口豆粕的依赖，保障粮食安全；还 能有效消化国内过剩的甲醇产能，有望打通从煤气、甲醇，到生物基新材料的产业链条。 这一许可基于微元合成全球首创的 ...

调研数据显示，2025年，在让自己和家人更健康的消费投入上，75.6%的消费者选择了营养保健品。其 中，有43%的人购买了1-2款营养保健产品，有36.2%的人购买了3-4款产品。维生素D、鱼油、氨糖、叶 黄素、蓟类提取物等相关营养保健产品位列大家选择前列。 当健康管理从"被动应对"转向"主动前置"，营养保健消费正迎来全方位的升级与重构。2025年，伴随全 民健康意识的深度觉醒，消费者对营养补充的需求愈发清晰、精准，不再满足于泛化的营养补充，而是 聚焦核心成分的功效适配、场景匹配与人群细分需求。 ● 调研显示，2025年，有43%的消费者购买了1-2款营养保健产品，36.2%的人购买了3-4款产品，成分认 知与功效匹配度成为影响购买决策的核心前提，维生素D、鱼油、氨糖、叶黄素、蓟类提取物等相关产 品位列购买选择前列，京东健康AI营养师"小晶"介绍，它们分别对应免疫与骨骼健康、心脑血管养 护、关节养护、眼部健康、肝脏养护五大核心健康需求。 ● 2025年，京东营养保健品类商品数量同比增长67%，京东健康通过引进更多品牌、拓宽品类价格带， 满足消费者对营养健康保健产品的多样化需求，其中，改善情绪、改善睡眠、孕产营 ...

Summary of the Conference Call for Morning Light Biological Company Overview - Morning Light Biological specializes in natural colorants, particularly chili red and chili extract, with a global market share of approximately 66% to 70% [2][3]. - The company is experiencing significant growth in sales, particularly in chili extract, which is expected to see a year-on-year growth rate of around 70% for the current year [2][5]. Industry Insights - The natural colorant industry is projected to maintain a natural growth rate of about 10% in the coming years, driven by increased penetration in mature markets and the development of the food industry in emerging markets [2][3]. - The market for lutein remains stable, with annual supply and sales around 400-500 million grams, showing no significant changes in market share [2][5]. Key Points - **Sales Growth**: Chili red and chili extract have seen historical peaks in sales, with chili extract's sales increasing by 80% in the first three quarters of the year [3][5]. - **Market Dynamics**: The increase in market share is expected to slow down as the market matures, with future growth relying more on natural industry growth rather than market share gains [3][5]. - **Cost Advantages**: Morning Light Biological has established a cost advantage through technological innovation and large-scale production, typically achieving production costs 5% to 10% lower than competitors [2][8]. - **Customized Solutions**: The company is focusing on customized solutions to enhance customer loyalty and product value, with customized products now accounting for 15% of sales [2][11]. Financial Performance - The company’s raw material procurement costs have remained stable compared to last year, despite a decrease in planting area for key raw materials [4][13]. - The health food contract manufacturing business is operating at nearly full capacity, with plans to expand production capacity by 50% next year [4][17]. Competitive Landscape - The competitive landscape in the plant extract industry is fragmented, with a few major players dominating larger product categories while smaller categories may have only one or two key competitors [6][7]. - Morning Light Biological's focus on technological innovation and efficiency gives it a competitive edge over many smaller firms in the industry [7][9]. Future Outlook - The company plans to maintain high levels of investment in research and development, particularly in customized product development, although a slight decrease in overall R&D expenses is expected in the coming years [16][18]. - The health food and traditional Chinese medicine sectors are expected to grow, with the latter projected to achieve breakeven in the near future [17][18]. Additional Considerations - The company is learning from international firms in the flavor and fragrance industry, which may influence its future growth strategies [22][23]. - The overall profitability of upstream farmers is currently low, which may impact raw material supply in the future [15]. This summary encapsulates the key insights and developments discussed during the conference call, providing a comprehensive overview of Morning Light Biological's current position and future prospects in the natural colorant industry.